Physician profile
Simon P Redmon
NPI 1528176807
$1,220.49
in general payments reported to CMS, 2019-2025
18 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $189 · 2022: $276 · 2023: $327 · 2024: $120 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $440.67 | 2021-2025 | |
| Pfizer INC. | $231.04 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.96 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $104.04 | 2021-2024 | Mounjaro |
| Novo Nordisk INC | $70.62 | 2024-2025 | Rybelsus, Ozempic |
| Amgen INC. | $40.51 | 2021-2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $34.54 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $21.55 | 2023 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $19.69 | 2023 | |
| Medtronic, INC. | $19.60 | 2022 | |
| Exact Sciences Corporation | $18.16 | 2025 | The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $17.86 | 2025 | Nexletol |
| Ibsa Pharma INC. | $16.96 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.36 | 2022 | |
| Astellas Pharma US INC | $15.32 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $13.38 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $12.87 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Redmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.